Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model

npj Vaccines

Volumn 2, Issue 1, 2017, Pages

  Munster, Vincent J ^a   Wells, Daniel ^b   Lambe, Teresa ^b   Wright, Daniel ^b   Fischer, Robert J ^a   Bushmaker, Trenton ^a   Saturday, Greg ^a   Van Doremalen, Neeltje ^a   Gilbert, Sarah C ^b   De Wit, Emmie ^a   Warimwe, George M ^b,c,d  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

^d KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85042178003     PISSN: None     EISSN: 20590105     Source Type: Journal    
DOI: 10.1038/s41541-017-0029-1     Document Type: Article

References (16)

1. Arabi, Y. M., et al. Middle East respiratory syndrome. N. Engl. J. Med. 376, 584-594 (2017).
2. Oboho, I. K., et al. 2014 MERS-CoV outbreak in Jeddah-a link to health care facilities. N. Engl. J. Med. 372, 846-854 (2015).
3. Reusken, C. B., et al. Geographic distribution of MERS coronavirus among dromedary camels, Africa. Emerg. Infect. Dis. 20, 1370-1374 (2014).
4. Modjarrad, K., et al. A roadmap for MERS-CoV research and product development: Report from a World Health Organization consultation. Nat. Med. 22, 701-705 (2016).
5. Ewer, K. J., et al. Viral vectors as vaccine platforms: From immunogenicity to impact. Curr. Opin. Immunol. 41, 47-54 (2016).
6. Dicks, M. D., et al. A novel chimpanzee adenovirus vector with low human seroprevalence: Improved systems for vector derivation and comparative immunogenicity. PLoS One 7, e40385 (2012).
7. Warimwe, G. M., et al. Chimpanzee adenovirus vaccine provides multispecies protection against rift valley fever. Sci. Rep. 6, 20617 (2016).
8. Alharbi, K. N., et al. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. Vaccine, https://doi.org/10.1016/j.vaccine.2017.05.032 (2017).
9. de Wit, E., van Doremalen, N., Falzarano, D., Munster, V. J. SARS and MERS: Recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 14, 523-534 (2016).
10. Agrawal, A. S., et al. Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. J. Virol. 89, 3659-3670 (2015).
11. Tao, X., et al. Characterization and demonstration of the value of a lethal mouse model of Middle East respiratory syndrome Coronavirus infection and disease. J. Virol. 90, 57-67 (2015).
12. van Doremalen, N., et al. High prevalence of middle east respiratory coronavirus in young dromedary camels in jordan. Vector Borne Zoonotic Dis. 17, 155-159 (2017).
13. Reusken, C. B., et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: A comparative serological study. Lancet Infect. Dis. 13, 859-866 (2013).
14. Ali, M. A., et al. Systematic, active surveillance for Middle East respiratory syndrome coronavirus in camels in Egypt. Emerg. Microbes Infect. 6, e1 (2017).
15. van Doremalen, N., et al. Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets. Antiviral Res. 143, 30-37 (2017).
16. de Wit, E., et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in transient lower respiratory tract infection in rhesus macaques Proc. Natl. Acad. Sci. USA 110, 16598-16603 (2013).